Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULAMYD versus SSD AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULAMYD versus SSD AF.
SODIUM SULAMYD vs SSD AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to bacterial DNA and cell wall components, causing disruption of cellular respiration and DNA replication. It also inhibits bacterial cell wall synthesis via the sulfadiazine component.
1-2 drops of 10% or 15% solution into affected eye(s) every 2-3 hours initially, tapered as infection resolves; ophthalmic ointment: apply 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
Apply a thin layer topically once or twice daily to affected area.
None Documented
None Documented
7-13 hours (prolonged in renal impairment; in anuria up to 22-50 hours)
Terminal elimination half-life is 6–8 hours; clinically, this supports twice-daily dosing in most patients.
Renal excretion of unchanged drug (approximately 70-100%) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (<5%)
Renal: ~10% as unchanged drug; biliary/fecal: ~90% as metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic